{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:19:38Z","timestamp":1766524778856,"version":"3.48.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1403-1-207-72086."],"award-info":[{"award-number":["1403-1-207-72086."]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-025-01615-3","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:43:40Z","timestamp":1761893020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A nationwide study on the consumption and expenditure of osteoporosis medications in Iran during the period from 2001 to 2021"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-7309","authenticated-orcid":false,"given":"Abdoreza","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noushin","family":"Fahimfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Ostovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Akbari Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff M, Lewiecki E, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"issue":"9773","key":"1615_CR2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. The Lancet 377(9773):1276\u20131287","journal-title":"The Lancet"},{"key":"1615_CR3","doi-asserted-by":"publisher","unstructured":"Fahimfar N, Noorali S, Yousefi S, Gharibzadeh S, Shafiee G, Panahi N et al (2021) Prevalence of osteoporosis among the elderly population of Iran. Arch Osteoporos 16: 16. Springer.   https:\/\/doi.org\/10.1007\/s11657-020-00872-8","DOI":"10.1007\/s11657-020-00872-8"},{"key":"1615_CR4","unstructured":"World Health Organization (2003) Prevention and management of osteoporosis. Geneva"},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:1\u2013115","journal-title":"Arch Osteoporos"},{"issue":"3","key":"1615_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/GRF.0b013e31825caa50","volume":"55","author":"R Pollycove","year":"2012","unstructured":"Pollycove R, Simon JA (2012) Osteoporosis: screening and treatment in women. Clin Obstet Gynecol 55(3):681\u2013691","journal-title":"Clin Obstet Gynecol"},{"issue":"11","key":"1615_CR7","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00198-022-06484-x","volume":"33","author":"A Ostovar","year":"2022","unstructured":"Ostovar A, Mousavi A, Sajjadi-Jazi SM, Rajabi M, Larijani B, Fahimfar N, Daroudi R (2022) The economic burden of osteoporosis in Iran in 2020. Osteoporos Int 33(11):2337\u20132346","journal-title":"Osteoporos Int"},{"issue":"1","key":"1615_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJ et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17(1):58","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1615_CR9","first-page":"105","volume":"133","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C (2020) The epidemiology of osteoporosis. Br Med Bull 133(1):105\u2013117","journal-title":"Br Med Bull"},{"issue":"3","key":"1615_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.5937\/hpimj1903857C","volume":"6","author":"\u0110M Cvjetkovi\u0107","year":"2019","unstructured":"Cvjetkovi\u0107 \u0110M, Cvjetkovi\u0107-Nedeljkovi\u0107 SM, Marti\u0107 NB, Sabo AJ, Tomi\u0107 ZS, Milija\u0161evi\u0107 B\u017d (2019) Analysis of utilization of bisphosphonates, strontium ranelate and denosumabe in Serbia, Finland, Norway and Denmark in the period 2013\u20132016. Hospital Pharmacology-International Multidisciplinary Journal 6(3):857\u2013867","journal-title":"Hospital Pharmacology-International Multidisciplinary Journal"},{"issue":"5","key":"1615_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.medici.2016.10.001","volume":"52","author":"O Laius","year":"2016","unstructured":"Laius O, Maasalu K, K\u00f5ks S, M\u00e4rtson A (2016) Use of drugs against osteoporosis in the Baltic countries during 2010\u20132014. Medicina 52(5):315\u2013320","journal-title":"Medicina"},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-017-0341-4","volume":"12","author":"O Laius","year":"2017","unstructured":"Laius O, Pisarev H, Maasalu K, K\u00f5ks S, M\u00e4rtson A (2017) Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004\u20132015. Arch Osteoporos 12:1\u20138","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1615_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.maturitas.2012.10.002","volume":"74","author":"ME Salgueiro","year":"2013","unstructured":"Salgueiro ME, Manso G, Castells X, Jimeno FJ, Ordo\u00f1ez L, Gonz\u00e1lez V et al (2013) Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008. Maturitas 74(1):74\u201378","journal-title":"Maturitas"},{"issue":"6","key":"1615_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199086","volume":"13","author":"G Sanf\u00e9lix-Gimeno","year":"2018","unstructured":"Sanf\u00e9lix-Gimeno G, Juli\u00e1-Sanchis M-L, Librero J, Peir\u00f3 S, Garc\u00eda-Sempere A (2018) Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain. Plos one. 13(6):e0199086","journal-title":"Plos one."},{"key":"1615_CR15","unstructured":"World Health Organization. ATC\/DDD Toolkit. Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit.  Accessed 5 May\u00a02024"},{"key":"1615_CR16","unstructured":"World Health Organization (2012) WHO collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment 2013. Oslo"},{"key":"1615_CR17","unstructured":"The World Bank . Available from:  https:\/\/data.worldbank.org\/country\/iran-islamic-rep.  Accessed 14 Feb\u00a02025"},{"key":"1615_CR18","unstructured":"Statistics Center of Iran.  Available from:  https:\/\/www.amar.org.ir\/statistical-information.  Accessed 15 Jan 2024"},{"key":"1615_CR19","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Available from:  https:\/\/www.whocc.no\/atc_ddd_index .  Accessed 30 Jul\u00a02023"},{"issue":"3","key":"1615_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/jrpp.JRPP_19_42","volume":"8","author":"H Abbasian","year":"2019","unstructured":"Abbasian H, Hajimolaali M, Yektadoost A, Zartab S (2019) Antibiotic utilization in Iran 2000\u20132016: pattern analysis and benchmarking with organization for economic co-operation and development countries. Journal of research in pharmacy practice 8(3):162\u2013167","journal-title":"Journal of research in pharmacy practice"},{"key":"1615_CR21","unstructured":"World Bank Open Data. Available from:   https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP?locations=IR.  Accessed 5 May 2024"},{"issue":"9","key":"1615_CR22","first-page":"759","volume":"18","author":"AD Irani","year":"2013","unstructured":"Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z (2013) Prevalence of osteoporosis in Iran: a meta-analysis. J Res Med Sci 18(9):759","journal-title":"J Res Med Sci"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-018-0540-7","volume":"13","author":"M Zamani","year":"2018","unstructured":"Zamani M, Zamani V, Heidari B, Parsian H, Esmaeilnejad-Ganji SM (2018) Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis. Arch Osteoporos 13:1\u201310","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1615_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/ijpvm.IJPVM_657_20","volume":"13","author":"H Nourmohammadi","year":"2022","unstructured":"Nourmohammadi H, Abdan Z, Hashemipour SMA, Sarokhani D, Abdan M, Fakhri M, Dehkordi AH (2022) Prevalence of osteoporosis and osteopenia in people over 60 years in Iran: a systematic review and meta-analysis. Int J Prev Med 13(1):11","journal-title":"Int J Prev Med"},{"issue":"3","key":"1615_CR25","first-page":"90","volume":"21","author":"F Hemati","year":"2018","unstructured":"Hemati F, Sarukhani D, Sayehmiri C, Motadayyen M (2018) Prevalence of osteoporosis in Iranian postmenopausal women: a systematic review and meta-analysis. Iranian Journal of Women, Obstetrics and Infertility 21(3):90\u2013102","journal-title":"Iranian Journal of Women, Obstetrics and Infertility"},{"key":"1615_CR26","first-page":"117954412110724","volume":"15","author":"T Eghbali","year":"2022","unstructured":"Eghbali T, Abdi K, Nazari M, Mohammadnejad E, Gheshlagh RG (2022) Prevalence of osteoporosis among Iranian postmenopausal women: a systematic review and meta-analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 15:11795441211072472","journal-title":"Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders"},{"key":"1615_CR27","doi-asserted-by":"crossref","unstructured":"Fahimfar N, Hesari E, Mansourzadeh MJ, Khalagi K, Sanjari M, Hajivalizadeh S et al (2023) Prevalence of osteoporosis in the Iranian population: a systematic review and meta-analysis. J Diabetes Metab Disord 23(1):229\u2013237","DOI":"10.1007\/s40200-023-01352-9"},{"issue":"5","key":"1615_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0002-9343(03)00357-7","volume":"115","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J (2003) Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 115(5):398\u2013400","journal-title":"Am J Med"},{"issue":"5","key":"1615_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1017\/S1463423618000014","volume":"19","author":"H Mahdaviazad","year":"2018","unstructured":"Mahdaviazad H, Keshtkar V, Emami MJ (2018) Osteoporosis guideline awareness among Iranian family physicians: results of a knowledge, attitudes, and practices survey. Primary health care research & development 19(5):485\u2013491","journal-title":"Primary health care research & development"},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32:251\u2013259","journal-title":"Osteoporos Int"},{"issue":"5","key":"1615_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00776-006-1050-9","volume":"11","author":"K Iba","year":"2006","unstructured":"Iba K, Takada J, Hatakeyama N, Kaya M, Isogai S, Tsuda H et al (2006) Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture. J Orthop Sci 11(5):446\u2013449","journal-title":"J Orthop Sci"},{"issue":"12","key":"1615_CR32","first-page":"e76047","volume":"16","author":"S Singh","year":"2024","unstructured":"Singh S, Patil S, Thein M, Kulkarni J, Kakroo AZ, Singh L et al (2024) A retrospective audit of osteoporosis management following fragility fractures in a hospital setting. Cureus 16(12):e76047","journal-title":"Cureus"},{"issue":"2","key":"1615_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11914-003-0010-y","volume":"1","author":"PP Geusens","year":"2003","unstructured":"Geusens PP (2003) Review of guidelines for testing and treatment of osteoporosis. Current osteoporosis reports 1(2):59\u201365","journal-title":"Current osteoporosis reports"},{"issue":"3","key":"1615_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 105(3):587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1615_CR35","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00198-023-06837-0","volume":"34","author":"EH Tan","year":"2023","unstructured":"Tan EH, Robinson DE, J\u00f6dicke AM, Mosseveld M, B\u00f8dkergaard K, Reyes C et al (2023) Drug utilization analysis of osteoporosis medications in seven European electronic health databases. Osteoporos Int 34(10):1771\u20131781","journal-title":"Osteoporos Int"},{"issue":"4","key":"1615_CR36","first-page":"600","volume":"20","author":"A Srinivasan","year":"2020","unstructured":"Srinivasan A, Wong FK, Karponis D (2020) Calcitonin: a useful old friend. J Musculoskelet Neuronal Interact 20(4):600","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1615_CR37","doi-asserted-by":"crossref","unstructured":"Hsiao F-Y, Hsu WW-Y (2017) Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study. Jpn J Clin Oncol 47(10):935\u201341","DOI":"10.1093\/jjco\/hyx111"},{"key":"1615_CR38","doi-asserted-by":"crossref","unstructured":"Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF et al (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 16(6):1016","DOI":"10.4158\/EP.16.6.1016"},{"issue":"9","key":"1615_CR39","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL et al (2016) American Association Of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142016\u2013executive summary. Endocr Pract 22(9):1111\u20131118","journal-title":"Endocr Pract"},{"key":"1615_CR40","doi-asserted-by":"crossref","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Clinical Guidelines Committee of the American College of Physicians, Cross Jr JT, Fitterman N, Lin JS, Maroto M, Obley AJ (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 176(2):224\u201338","DOI":"10.7326\/M22-1034"},{"issue":"2","key":"1615_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jsps.2017.12.005","volume":"26","author":"B Balkhi","year":"2018","unstructured":"Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R (2018) Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharmaceutical Journal 26(2):238\u2013243","journal-title":"Saudi Pharmaceutical Journal"},{"key":"1615_CR42","first-page":"39","volume":"31","author":"AAEF Azar","year":"2017","unstructured":"Azar AAEF, Rezapour A, Alipour V, Sarabi-Asiabar A, Gray S, Mobinizadeh M et al (2017) Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran. Med J Islam Repub Iran 31:39","journal-title":"Med J Islam Repub Iran"},{"issue":"2","key":"1615_CR43","first-page":"1073","volume":"18","author":"S Taheri","year":"2019","unstructured":"Taheri S, Fashami FM, Peiravian F, Yousefi N (2019) Teriparatide in the treatment of severe postmenopausal osteoporosis: a cost-utility analysis. Iranian journal of pharmaceutical research: IJPR 18(2):1073","journal-title":"Iranian journal of pharmaceutical research: IJPR"},{"key":"1615_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00774-019-01061-5","volume":"38","author":"K-L Wu","year":"2020","unstructured":"Wu K-L, Wu C-H, Chang Y-F, Lin Y-T, Hsu JC (2020) Budget impact analysis of osteoporosis medications for primary prevention of fractures in Taiwan. J Bone Miner Metab 38:316\u2013327","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"1615_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18579\/jpcrkc\/2017\/16\/1\/112466","volume":"16","author":"AM Cheraghali","year":"2017","unstructured":"Cheraghali AM (2017) Trends in Iran pharmaceutical market. Iranian journal of pharmaceutical research: IJPR 16(1):1\u20137","journal-title":"Iranian journal of pharmaceutical research: IJPR"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01615-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:17:00Z","timestamp":1766524620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01615-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01615-3","relation":{},"ISSN":["1862-3514"],"issn-type":[{"type":"electronic","value":"1862-3514"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"138"}}